Abstract
Metastatic colorectal cancer with BRAF mutation is a type of highly invasive malignant tumor with poor prognosis and few treatment options. Here, we report a case of a BRAF-mutant and DNA mismatch-repair deficiency colorectal cancer patient with postoperative recurrence as well as abdominal cavity and pelvic metastasis, whose condition was relieved continuously after treatment with a new anti-PD-1 antibody, BGB-A317.
Keywords:
BRAF mutation; DNA mismatch repair deficiency; PD-1 inhibitors; advanced colorectal cancer; high microsatellite instability; immunotherapy.
MeSH terms
-
Abdominal Neoplasms / drug therapy
-
Abdominal Neoplasms / genetics
-
Abdominal Neoplasms / secondary
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / genetics
-
Adenocarcinoma / secondary
-
Aged
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Biomarkers, Tumor / genetics
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / genetics
-
Colorectal Neoplasms / pathology*
-
DNA Mismatch Repair / genetics*
-
Female
-
Humans
-
Immune Checkpoint Inhibitors / therapeutic use*
-
Immunotherapy
-
Microsatellite Instability
-
Mutation
-
Pelvic Neoplasms / drug therapy
-
Pelvic Neoplasms / genetics
-
Pelvic Neoplasms / secondary
-
Proto-Oncogene Proteins B-raf / genetics*
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
Biomarkers, Tumor
-
Immune Checkpoint Inhibitors
-
tislelizumab
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf